The agreement includes Cardior's lead compound CDR132L, currently being investigated in a Phase II clinical trial (HF-REVERT) for the treatment of heart failure.
The deal comprises an upfront payment, plus additional payments if certain development and commercial milestones are achieved.
CDR132L is designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132, potentially leading to long-lasting improvement in heart function.
"We have been impressed by the scientific work carried out by the Cardior team, especially on CDR132L, which has a distinctive mode of action and potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people living with heart failure," commented
A Phase Ib trial of CDR132L, published in the
CDR132L is currently being investigated in 280 people with heart failure with reduced ejection fraction (HFrEF) who have previously suffered a heart attack (myocardial infarction). The first patient was dosed in the HF-REVERT trial in
This acquisition is a reflection of CDR132L's transformative potential as a disease-modifying therapy for heart failure”
The acquisition of Cardior is a in important step forward in
"This acquisition is a reflection of CDR132L's transformative potential as a disease-modifying therapy for heart failure," said
The transaction is expected to close in the second quarter of 2024, subject to receipt of applicable regulatory approvals and other customary conditions.
Regenerative potential: cell‑based therapies for heart failure
The post
© Russell Publishing Limited, 2024. All Rights Reserved., source